Trombosit Refrakterliği Olan Glanzmann Trombastenili Hastada Travmatik Hifemanın Rekombinan Faktör VIIa ile Başarılı Tedavisi
Abstract
Glanzmann trombastenisi (GT) yaşam boyu kanamaya yatkınlıkla karakterize olan trombosit agregasyonunun kalıtımsal bozukluğudur. Glanzmann Trombastenisinin göz bulgularıyla nadiren karşılaşılır. Standart tedavi trombosit transfüzyonudur; bununla birlikte tekrarlanan transfüzyonlar trombosite karşı antikor oluşumu ve trombosit refrakterliği ile sonuçlanmaktadır. Rekombinan aktif faktör VIIa (rFVIIa) trombosit antikoru ve/veya trombosit refrakterliği olan GT hastalarda efektif alternatif bir tedavidir. Burada rFVIIa ile başarılı bir şekilde tedavi edilen travmatik hifeması olan GT’li bir hastayı sunduk.
References
- Nurden AT. Qualitative disorders of platelets and megakaryocytes. J Thromb Haemost 2005;3:1773-82.
- Nurden AT. Glanzmann thrombasthenia. Orphanet J Rare Dis 2006;1:10.
- Hod E, Schwartz J. Platelet transfusion refractoriness. Br J Haematol 2008;142: 348-60.
- Poon MC. The evidence for the use of recombinant human activated factor VII in the treatment of bleeding patients with quantitative and qualitative platelet disorders. Transfus Med Rev 2007;21:223-36.
- Maggs PB, MJ, Chalmers EA, Collins PW. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol 2006;135:603-33.
- Kamburoğlu G, Kiratli H. Recurrent traumatic hyphema in a patient with Glanzmann thrombasthenia. J AAPOS 2005;10:186-7.
- Slichter SJ. Evidence-based platelet transfusion guidelines. Hematology Am Soc Hematol Educ Program 2007;172-8.
- Santoro C, Rago A, Biondo F, Conti L, Pulcinelli F, Laurenti L, et al. Prevalence of allo-immunization anti-HLA and anti- integrin alphaIIbbeta3 in Glanzmann Thromboasthenia patients. Haemophilia 2010;16:805-12.
- Salama ME, Raman S, Drew MJ, Abdel-Raheem M, Mahmood MN. Platelet function testing to assess effectiveness of platelet transfusion therapy. Transfus Apher Sci 2004;30:93-100.
- Poon MC, d’Oiron R, Zotz RB, Bindslev N, Di Minno MC, Di Minno G. The international, prospective Glanzmann Thrombasthenia Registry: Treatment and outcomes in surgical intervention Haematologica 2015;100:1038-44.
- Coller BS, French DL. Hereditary qualitative platelet disorders. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U (eds). Williams Hematology, 6th ed. New York: McGraw-Hill, 2001: 1551- 60.
- Galan AM, Tonda R, Pino M, Reverter JC, Ordinas A, Escolar G. Increased local procoagulant action: A mechanism contributing to the favorable hemostatic effect of recombinant FVIIa in PLT disorders. Transfusion 2003;43:885-92.
- Nurden AT, Pillois X, Wilcox DA. Glanzmann thrombasthenia: State of the art and future directions. Semin Thromb Hemost 2013;39:642–55.
- Solh T, Botsford A, Solh M. Glanzmann’s thrombasthenia: Pathogenesis, diagnosis, and current and emerging treatment options. J Blood Med 2015;6:219-27.
Traumatic Hyphema Successfully Treated with Recombinant Factor VIIa in Glanzmann Thrombasthenia with Platelet
Abstract
Glanzmann thrombasthenia (GT) is a congenital disorder of platelet aggregation characterized by a lifelong bleeding tendency. Standard therapy consists of platelet transfusions; however repeated transfusions may result in antiplatelet antibodies and platelet refractoriness. Recombinant activated factor VII (rFVIIa) is an effective alternative therapy in GT patients, particularly in those with antiplatelet antibodies and/or platelet refractoriness. Ocular manifestations of GT are very rare. Here we report a case of GT with traumatic hyphema who was successfully treated with rFVIIa
References
- Nurden AT. Qualitative disorders of platelets and megakaryocytes. J Thromb Haemost 2005;3:1773-82.
- Nurden AT. Glanzmann thrombasthenia. Orphanet J Rare Dis 2006;1:10.
- Hod E, Schwartz J. Platelet transfusion refractoriness. Br J Haematol 2008;142: 348-60.
- Poon MC. The evidence for the use of recombinant human activated factor VII in the treatment of bleeding patients with quantitative and qualitative platelet disorders. Transfus Med Rev 2007;21:223-36.
- Maggs PB, MJ, Chalmers EA, Collins PW. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol 2006;135:603-33.
- Kamburoğlu G, Kiratli H. Recurrent traumatic hyphema in a patient with Glanzmann thrombasthenia. J AAPOS 2005;10:186-7.
- Slichter SJ. Evidence-based platelet transfusion guidelines. Hematology Am Soc Hematol Educ Program 2007;172-8.
- Santoro C, Rago A, Biondo F, Conti L, Pulcinelli F, Laurenti L, et al. Prevalence of allo-immunization anti-HLA and anti- integrin alphaIIbbeta3 in Glanzmann Thromboasthenia patients. Haemophilia 2010;16:805-12.
- Salama ME, Raman S, Drew MJ, Abdel-Raheem M, Mahmood MN. Platelet function testing to assess effectiveness of platelet transfusion therapy. Transfus Apher Sci 2004;30:93-100.
- Poon MC, d’Oiron R, Zotz RB, Bindslev N, Di Minno MC, Di Minno G. The international, prospective Glanzmann Thrombasthenia Registry: Treatment and outcomes in surgical intervention Haematologica 2015;100:1038-44.
- Coller BS, French DL. Hereditary qualitative platelet disorders. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U (eds). Williams Hematology, 6th ed. New York: McGraw-Hill, 2001: 1551- 60.
- Galan AM, Tonda R, Pino M, Reverter JC, Ordinas A, Escolar G. Increased local procoagulant action: A mechanism contributing to the favorable hemostatic effect of recombinant FVIIa in PLT disorders. Transfusion 2003;43:885-92.
- Nurden AT, Pillois X, Wilcox DA. Glanzmann thrombasthenia: State of the art and future directions. Semin Thromb Hemost 2013;39:642–55.
- Solh T, Botsford A, Solh M. Glanzmann’s thrombasthenia: Pathogenesis, diagnosis, and current and emerging treatment options. J Blood Med 2015;6:219-27.
Details
| Other ID | JA45YH23YH |
|---|---|
| Journal Section | Case Report |
| Authors | |
| Publication Date | April 1, 2017 |
| Submission Date | April 1, 2017 |
| Published in Issue | Year 2017 Volume: 11 Issue: 1 |
The publication language of Turkish Journal of Pediatric Disease is English.
Manuscripts submitted to the Turkish Journal of Pediatric Disease will go through a double-blind peer-review process. Each submission will be reviewed by at least two external, independent peer reviewers who are experts in the field, in order to ensure an unbiased evaluation process. The editorial board will invite an external and independent editor to manage the evaluation processes of manuscripts submitted by editors or by the editorial board members of the journal. The Editor in Chief is the final authority in the decision-making process for all submissions. Articles accepted for publication in the Turkish Journal of Pediatrics are put in the order of publication, with at least 10 original articles in each issue, taking into account the acceptance dates. If the articles sent to the reviewers for evaluation are assessed as a senior for publication by the reviewers, the section editor and the editor considering all aspects (originality, high scientific quality and citation potential), it receives publication priority in addition to the articles assigned for the next issue.
The aim of the Turkish Journal of Pediatrics is to publish high-quality original research articles that will contribute to the international literature in the field of general pediatric health and diseases and its sub-branches. It also publishes editorial opinions, letters to the editor, reviews, case reports, book reviews, comments on previously published articles, meeting and conference proceedings, announcements, and biography. In addition to the field of child health and diseases, the journal also includes articles prepared in fields such as surgery, dentistry, public health, nutrition and dietetics, social services, human genetics, basic sciences, psychology, psychiatry, educational sciences, sociology and nursing, provided that they are related to this field. can be published.